Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. (2023)
Attributed to:
JPND GBA - personalised medicine for Parkinson disease: clinical and therapeutic stratification
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.pharmthera.2023.108419
PubMed Identifier: 37080432
Publication URI: http://europepmc.org/abstract/MED/37080432
Type: Journal Article/Review
Volume: 246
Parent Publication: Pharmacology & therapeutics
ISSN: 0163-7258